Drospinita 4 Mg28 Tablets

Drospinita 4 Mg28 Tablets

Description:

Drospinita 4 mg 28 tablets is a prescription oral hormonal contraceptive medicine containing drospirenone, a synthetic progestin. It is indicated for use by females of reproductive potential to prevent pregnancy. The pack follows a 24 + 4 dosing regimen, providing 24 active hormone film-coated tablets and 4 placebo tablets to support regular daily intake and cycle control. Manufactured by Marcyrl Pharmaceutical Industries (MPI), Drospinita offers effective, once-daily birth control when used correctly under medical supervision.

Indications:

• Prevention of pregnancy in females of reproductive age.
• Contraception for women who prefer a progestin-only oral contraceptive containing drospirenone.
• May help regulate menstrual bleeding patterns in some users (under physician supervision).
• May reduce menstrual cramps and cycle-related discomfort in some women (individual response varies).

Active Ingredients / Key Components:

• Drospirenone – 4 mg per active film-coated tablet.
• Placebo tablets – contain no active hormonal ingredient (excipients only; exact composition not available).
• Other inactive ingredients/excipients: detailed full excipient list is not available in the provided data; please refer to the official package leaflet for complete information.

Dosage & Administration / How to Use:

• Drospinita is for oral use only and must be taken exactly as prescribed by a healthcare professional.
• Standard regimen: one tablet daily at the same time each day, following the 24 + 4 schedule in the blister pack (24 active tablets followed by 4 placebo tablets).
• Start of use (first pack): typically started on the first day of menstrual bleeding or as directed by the doctor. Alternative start protocols (e.g., day 2–5 start or switching from another contraceptive) must follow medical advice.
• Tablet sequence: follow the arrows and numbering on the blister strip without interruption, taking one tablet every day until all 28 tablets are finished, then immediately start a new pack the next day.
• With or without food: tablets may be taken with or without food, swallowed whole with water; do not chew or crush.
• Missed dose: if a tablet is missed, follow the specific missed-pill instructions in the patient leaflet or as advised by your doctor or pharmacist. Depending on how many hours have passed and how many tablets were missed, additional contraceptive protection (e.g., condoms) may be required.
• Vomiting/diarrhea: severe vomiting or diarrhea within a few hours of taking a tablet may reduce effectiveness; an additional tablet may be needed according to the leaflet instructions and medical advice.
• Duration of use: can be used long term for contraception as long as no contraindications arise and regular medical follow-up is maintained.
• Do not exceed the prescribed daily dose. Do not stop or change your regimen without consulting your healthcare provider.

Clinical Benefits:

• Provides reliable hormonal contraception when taken correctly, helping effectively prevent unintended pregnancy.
• Progestin-only formulation with drospirenone 4 mg may be suitable for certain women who cannot use estrogen-containing combined oral contraceptives, based on physician evaluation.
• 24 + 4 regimen supports better adherence and routine by ensuring tablet intake every day of the cycle, reducing the chance of forgetting pills.
• May contribute to more predictable bleeding patterns and reduction of menstrual cramps for some users, improving overall cycle comfort and quality of life.

Warnings & Contraindications:

• Use only under the supervision of a qualified healthcare professional. A full medical history and assessment are required before starting Drospinita.
• Contraindicated in women with known or suspected pregnancy.
• Contraindicated in women with active or history of venous thromboembolism (deep vein thrombosis, pulmonary embolism) or arterial thromboembolic disease, unless your doctor specifically decides otherwise based on current guidelines.
• Contraindicated in severe renal impairment, acute renal failure, or conditions predisposing to hyperkalemia (elevated potassium levels), as drospirenone has antimineralocorticoid activity.
• Contraindicated in severe liver disease, liver tumors, or unexplained vaginal bleeding until properly evaluated.
• Not suitable for women with known hypersensitivity or allergy to drospirenone or any of the excipients.
• Caution in women with risk factors for blood clots, cardiovascular disease, hypertension, diabetes with vascular involvement, migraine with aura, or obesity; your doctor will assess the benefit–risk balance.
• Use with caution in patients taking other medicines that increase serum potassium (e.g., certain diuretics, ACE inhibitors, angiotensin II receptor blockers, potassium supplements, NSAIDs in high doses); potassium monitoring may be required.
• Does not protect against HIV (AIDS) or other sexually transmitted infections (STIs); barrier protection (e.g., condoms) is needed for STI prevention.
• Consult your doctor before use if pregnant, nursing, taking medications, or have medical conditions such as liver disease, kidney disease, adrenal disease, history of thrombosis, hormone-sensitive cancers, or severe migraines.
• Not intended to diagnose, treat, cure, or prevent any disease.
• Keep out of reach of children.
• In case of overdose or ingestion by a child, seek medical advice immediately.

Side Effects:

• Common side effects may include headache, breast tenderness, mood changes, nausea, abdominal pain, irregular uterine bleeding or spotting, and changes in menstrual flow.
• Other possible effects include weight changes, acne or skin changes, decreased libido, or fluid retention; not all users will experience these effects.
• Serious but less common side effects may include signs of blood clots (sudden leg pain, chest pain, shortness of breath), severe headache, visual disturbances, jaundice, severe abdominal pain, or significant increase in blood pressure.
• Stop taking the product and seek immediate medical attention if you experience symptoms of a possible blood clot, severe allergic reaction (swelling of face, lips, tongue, difficulty breathing), or any sudden severe symptom.
• If you notice persistent or bothersome side effects, contact your doctor or pharmacist for evaluation and advice.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children.

Specifications:

• Product type: oral hormonal contraceptive medicine.
• Active ingredient strength: drospirenone 4 mg per active film-coated tablet.
• Pack size: 28 film-coated tablets (24 active tablets + 4 placebo tablets).
• Form: tablets for oral use.
• Intended users: females of reproductive age as prescribed by a healthcare professional.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.